Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions -: Update on a randomized phase III trial of the German CLL study group (GCLLSG).

被引：0
|
作者：
Ritgen, M
Schweighofer, C
Fingerle-Rowson, G
Eichhorst, B
Busch, R
Stilgenbauer, S
Döhner, H
Kneba, M
Hallek, M
Wendtner, CM
机构：
[1] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany
[2] Univ Hosp, Med Clin 1, Colone, Germany
[3] Klinikum Grosshadern, Med Clin 3, Munich, Germany
[4] Tech Univ Munich, Inst Med Stat & Epidemiol, D-8000 Munich, Germany
[5] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2506
引用
收藏
页码：687A / 687A
页数：1
相关论文
共 35 条
  • [1] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG).
    Wendtner, CM
    Ritgen, M
    Schweighofer, CD
    Fingerle-Rowson, G
    Campe, H
    Jaeger, G
    Eichhorst, B
    Busch, R
    Diem, H
    Engert, A
    Stilgenbauer, S
    Doehner, H
    Kneba, M
    Emmerich, B
    Hallek, M
    BLOOD, 2003, 102 (11) : 676A - 676A
  • [2] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
    C-M Wendtner
    M Ritgen
    C D Schweighofer
    G Fingerle-Rowson
    H Campe
    G Jäger
    B Eichhorst
    R Busch
    H Diem
    A Engert
    S Stilgenbauer
    H Döhner
    M Kneba
    B Emmerich
    M Hallek
    Leukemia, 2004, 18 : 1093 - 1101
  • [3] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission -: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
    Wendtner, CM
    Ritgen, M
    Schweighofer, CD
    Fingerle-Rowson, G
    Campe, H
    Jäger, G
    Eichhorst, B
    Busch, R
    Diem, H
    Engert, A
    Stilgenbauer, S
    Döhner, H
    Kneba, M
    Emmerich, B
    Hallek, M
    LEUKEMIA, 2004, 18 (06) : 1093 - 1101
  • [4] Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission-long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
    Schweighofer, C.
    Ritgen, M.
    Eichhorst, B.
    Busch, R.
    Kneba, M.
    Hallek, M.
    Wendtner, Clemens
    BLOOD, 2006, 108 (11) : 14A - 14A
  • [5] Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
    Schweighofer, Carmen D.
    Ritgen, Matthias
    Eichhorst, Barbara F.
    Busch, Raymonde
    Abenhardt, Wolfgang
    Kneba, Michael
    Hallek, Michael
    Wendtner, Clemens-Martin
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (01) : 95 - 98
  • [6] TPLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL
    Hopfinger, Georg
    Busch, Raymond
    Barbara, Eichhorst
    Paula, Cramer
    Gabriele, Kandler
    Gunther, Fingerle-Rowson
    Anna-Maria, Fink
    Stephan, Stilgenbauer
    Michael, Hallek
    BLOOD, 2007, 110 (11) : 607A - 607A
  • [7] Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG)
    Fischer, Kirsten
    Cramer, Paula
    Stilgenbauer, Stephan
    Busch, Raymonde
    Balleisen, Leopold
    Kilp, Julia
    Fink, Anna-Maria
    Boettcher, Sebastian
    Ritgen, Matthias
    Kneba, Michael
    Staib, Peter
    Doehner, Hartmut
    Schulte, Silke
    Eichhorst, Barbara F.
    Hallek, Michael
    Wendtner, Clemens-Martin
    BLOOD, 2009, 114 (22) : 89 - 89
  • [8] T-PLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL.
    Hopfinger, G
    Busch, R
    Eichhorst, B
    Kandler, G
    Wendtner, C
    Hallek, M
    BLOOD, 2005, 106 (11) : 602A - 603A
  • [9] Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG)
    Kovacs, Gabor
    Boettcher, Sebastian
    Bahlo, Jasmin
    Kluth, Sandra
    Ritgen, Matthias
    Fink, Anna Maria
    Stodden, Irene
    Cramer, Paula
    von Tresckow, Julia
    Maurer, Christian
    Doehner, Hartmut
    Stilgenbauer, Stephan
    Kneba, Michael
    Fischer, Kirsten
    Hallek, Michael
    Eichhorst, Barbara
    BLOOD, 2014, 124 (21)
  • [10] T-PLL-1 protocol of the German CLL study group (GCLLSG) - a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation as first-line treatment in T-PLL.
    Hopfinger, G
    Kandler, G
    Koller, E
    Schmitt, B
    Aul, C
    Frickhofen, N
    Grabenhorst, U
    Herold, M
    Jaeger, U
    Marquart, F
    Busch, R
    Hallek, M
    BLOOD, 2003, 102 (11) : 674A - 674A
1234